News and Events

Impact of COVID-19 on cancer services to end of February

14 April 2022

The Cancer Control Agency Te Aho o Te Kahu continues to monitor the impact of COVID-19 on cancer diagnostic and treatment services.  The most recent report includes DHB data up until the end of February 2022. 

Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040

31 March 2022

According to this recent epidemiological assessment, melanoma remains an important challenge to cancer control and public health globally, especially in fair-skinned populations of European descent. The highest incidence rates were observed in Australia/New Zealand. Mortality rates peaked at 5 per 100 000 person-years in New Zealand.

Antifibrotic drugs as therapeutic tools in resistant melanoma

18 March 2022

In this issue of EMBO Molecular Medicine, Diazzi et al (2022) identify a mechanism regulating MAPKiinduced phenotypic plasticity and resistance, providing evidence to support the use of an anti-fibrotic drug as a potential novel combinatorial therapeutic approach in melanoma treatment.

Pathologic response of index lymph node may be considered reliable indicator of entire therapeutic lymph node dissection after neoadjuvant checkpoint inhibitor therapy in stage III melanoma patients

18 March 2022

The objective of this study was to assess the concordance of response between the index lymph node (ILN) and the total lymph node bed in a larger clinical trial population. Results of the study suggest that the pathologic response of the ILN may be considered a reliable indicator of the entire therapeutic lymph node dissection (TLND) specimen response and may support the ILN response-directed omission of TLND in a prospective trial.

Current evidence for neoadjuvant systemic therapy​ in stage III melanoma

15 March 2022

Authors of this paper describe the state of the science of neoadjuvant systemic therapy (NAST) for melanoma, focusing on the surgical aspects and the key role of the surgical oncologist in this treatment paradigm. The paper summarizes the past decade of developments in melanoma treatment and the current evidence for NAST in stage III melanoma specifically.